Goflikicept: a new promising drug for the treatment of recurrent pericarditis

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Recurrent idiopathic pericarditis is an autoimmune inflammatory disease of the pericardium characterized by repeated episodes of inflammation after 4–6 weeks of remission. This article examines the historical development and current understanding of the pathogenesis of recurrent pericarditis as an interleukin-1 (IL-1)-dependent autoinflammatory disease. It describes the efficacy of targeted therapy compared to standard treatments and the advantages of goflikicept, the first and only Russian drug, compared to other IL-1 antagonists. The paper also examines the results of a study of its safety profile and efficacy during long-term therapy.

全文:

受限制的访问

作者简介

A. Vydashenko

Order of the Red Banner of Labor Institute named after S.I. Georgievsky

Email: denis.elagin@vk.com
ORCID iD: 0000-0002-0351-8185
俄罗斯联邦, Simferopol

D. Elagin

Order of the Red Banner of Labor Institute named after S.I. Georgievsky

编辑信件的主要联系方式.
Email: denis.elagin@vk.com
ORCID iD: 0009-0006-6252-0636
SPIN 代码: 2546-8230

Student

俄罗斯联邦, Simferopol

M. Sheremet

Order of the Red Banner of Labor Institute named after S.I. Georgievsky

Email: denis.elagin@vk.com
ORCID iD: 0009-0003-2011-0805
俄罗斯联邦, Simferopol

参考

  1. Клинические рекомендации. Перикардиты. 2022-2023-2024 (10.11.2022). Утверждены Минздравом РФ. [Clinical guidelines. Pericarditis. 2022-2023-2024 (10.11.2022). Approved by the Ministry of Health of the Russian Federation. (In Russ.)].
  2. Vlachakis P.K., Theofilis P., Soulaidopoulos S., et al. Clinical Utility of Rilonacept for the Treatment of Recurrent Pericarditis: Design, Development, and Place in Therapy. Drug Des Devel Ther. 2024;18:3939–50. https://doi.org/10.2147/DDDT.S261119
  3. Lopalco G., Rigante D., Cantarini L., et al. The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. Trends Cardiovasc Med. 2021;31(5):265–74.
  4. Dressler W. A post-myocardial infarction syndrome; preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis. J Am Med Associat. 1956;160(16). https://doi.org/10.1001/jama.1956.02960510005002
  5. Dressler W. The post-myocardial-infarction syndrome: a report on forty-four cases. AMA Arch Int Med. 1959;103(1):28–42. https://doi.org/10.1001/archinte.1959.00270010034006
  6. Pankuweit S., Stein A., Karatolios K., et al. Viral genomes in the pericardial fluid and in peri- and epicardial biopsies from a German cohort of patients with large to moderate pericardial effusions. Heart Failure Rev. 2013;18(3). https://doi.org/10.1007/s10741-013-9375-x
  7. Мячикова В.Ю. Идиопатический рецидивирующий перикардит и болезнь Стилла взрослых в спектре аутовоспалительных заболеваний. Дисс. канд. мед. наук. М., 2023. [Myachikova V.Yu. Idiopathic recurrent pericarditis and Still’s disease in adults in the spectrum of autoinflammatory diseases. Diss. Cand. of Med. Sciences. Moscow, 2023. (In Russ.)].
  8. Mauro A.G., Bonaventura A., Vecchié A., et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC: Basic to Translational Science. 2021;6(2):137–50.
  9. Samsonov M., Bogin V., Van Tassell B.W., Abbate A. Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. J Transl Med. 2021;19(1):169. https://doi.org/10.1186/s12967-021-02828-z
  10. Tombetti E., Giani T., Brucato A., Cimaz R. Recurrent pericarditis in children and adolescents. Front Pediatr. 2019;(7):419.
  11. Markel G., Imazio M., Koren-Morag N., et al. CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis. Oncotarget. 2016;7(14):17885–95.
  12. Adler Y., Charron P., Imazio M., et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–64. https://doi.org/10.1093/eurheartj/ehv318
  13. Havnaer A., Han G. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment. Am J Clin Dermatol. 2019;20(4):539–64. https://doi.org/10.1007/s40257-019-00440-y
  14. Ammirati E., Bizzi E., Veronese G., et al. Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. Front Med (Lausanne). 2022;7(9):564. https://doi.org/https://doi.org/10.3389/fmed.2022.838564
  15. Imazio M., Bobbio M., Cecchi E., et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987–91. https://doi.org/10.1001/archinte.165.17.1987
  16. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4(3):252–6. https://doi.org/10.1007/s11926-002-0073-2.
  17. Imazio M., Brucato A., Cumetti D., et al. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation. 2008;118(6):667–71. https://doi.org/10.1161/CIRCULATIONAHA.107.761064
  18. Brucato A., Brambilla G., Moreo A., et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol. 2006;98(2):267–71. https://doi.org/10.1016/j.amjcard.2006.01.086
  19. Imazio M., Spodick D.H., Brucato A., et al. Controversial issues in the management of pericardial diseases. Circulation. 2010;121(7):916–28. https://doi.org/10.1161/CIRCULATIONAHA.108.844753
  20. Picco P., Brisca G., Traverso F., et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthrit Rheumatol. 2009;60(1):264–8.
  21. Brucato A., Imazio M., Gattorno M., et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. J Am Med Associat. 2016;316(18):1906–12.
  22. Klein A.L., Imazio M., Brucato A., et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228(10):81–90.
  23. Betrains A., Staels F., Schrijvers R., et al. Systemic autoinflammatory disease in adults. Autoimmun Rev. 2021;20(4). https://doi.org/10.1016/j.autrev.2021.102774
  24. Арцерикс [Электронный ресурс]: инструкция по применению. VIDAL. [Arcerix [Electronic resource]: instructions for use. VIDAL. (In Russ.)]. URL: https://www.vidal.ru/drugs/artseriks (дата обращения / date of access: 10.04.2025).
  25. Desai D., Maheta D., Agrawal S.P., et al. Comparative efficacy and safety of colchicine and interleukin-1 antagonists in recurrent pericarditis: a network meta-analysis. Panminerva Med. 2024;67(1). https://doi.org/10.23736/S0031-0808.24.05269-8
  26. Samsonov M., Bogin V., Van Tassell B.W., Abbate A. Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. J Transl Med. 2021;19(1):169. https://doi.org/10.1186/s12967-021-02828-z
  27. Dmitrieva A., Shipaeva E., Schedrova M., Scott M., Lavrovsky Y., Samsonov M. Nonclinical characterization of the novel IL-1 heterodimeric fusion protein RPH-104. Immunome Res. 2018;14:47. https://doi.org/10.4172/1745-7580-c1-014
  28. Myachikova V.Y., Maslyanskiy A.L., Moiseeva O.M., et al. Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results. J Am Coll Cardiol. 2023;82(1):30–40. https://doi.org/10.1016/j.jacc.2023.04.046
  29. Мячикова В.Ю., Маслянский А.Л., Моисеева О.М. и др. Длительное лечение гофликицептом пациентов с идиопатическим рецидивирующим перикардитом: данные промежуточного анализа открытого продленного исследования. Терапевтический архив. 2024;96(9):892–900. [Myachikova V.Yu., Maslyanskiy A.L., Moiseeva O.M., et al. Long-term goflkicept therapy for patients with idiopathic recurrent pericarditis: results of the interim analysis of an ongoing open-label extension study. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(9):892–900. (In Russ.)]. https://doi.org/10.26442/00403660.2024.09.202984

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025